PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2-positive early breast cancer

Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar- trastuzumab) in the US and Canada

Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar- trastuzumab) in the US and Canada

October 1, 2020

Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer After Surgery

Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer A...

November 29, 2019

Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

October 15, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us